Optimization of human iPS cell derived liver bud transplantation

2017 Fiscal Year Final Research Report

• Project/Area Number: 15H05677
• Research Category: Grant-in-Aid for Young Scientists (A)
• Allocation Type: Single-year Grants
• Research Field: General surgery
• Research Institution: Yokohama City University
• Principal Investigator: TAKEBE Takanori 横浜市立大学, 先端医科学研究センター, 教授 (20612625)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 再生医学 / 移植外科学

Outline of Final Research Achievements

Organoid technology provides a revolutionary paradigm towards therapy, yet to be applied in humans mainly because of the reproducibility and scalability challenges. Here, we overcome these limitations by evolving scalable organ bud production platform entirely from human iPSC. First, we identified effective progenitor populations for generating liver buds in a highly reproducible manner: hepatic endoderm, endothelium and septum mesenchyme. Furthermore, we achieved human scalability by developing an omni-well-array culture platform for mass-producing homogenous and miniaturized liver buds on a large scale (>108-scale). Vascularized and functional liver tissues generated entirely from iPSC significantly improved subsequent hepatic functionalization, enabling functional rescue against acute liver failure via transplantation. Overall, our study provides a stringent manufacture platform for multi-cellular organoid supply, thus facilitating clinical and pharmaceutical applications.

Free Research Field

再生医学